Skip to main content

Invitrogen Chief Lyle Turner to Step Down Jan. 1; CEO, Chair Posts to Split

NEW YORK, Dec. 5 - Lyle Turner, the gregarious founder, CEO, and chairman of Invitrogen, will step down at the end of the year, the company said today.


James Glynn, Invitrogen's executive vice president and former CFO, has been named president and COO. When Turner leaves Jan. 1, Glynn will assume the role of interim CEO until a permanent chief is hired. Bradley Lorimier, a current board member, will become chairman.


Invitrogen said it hopes to have a new CEO in place before the end of June, though the company said it has no specific timeline.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.